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A B S T R A C T
We present our experience with primary CO2 laser surgery for planocellular supraglottic carcinoma. During a ten-
-year period, we performed 64 curative supraglottic laryngectomies. Twenty-nine patients presented with T1 and 35 with
T2 carcinoma. There were 46 patients without regional and/or distant metastases (N0 neck), and 18 patients with N+
neck. Thirty-three (52%) patients were treated with surgery alone, and in 31 (48%) patients surgical procedure was com-
bined with radiotherapy. Estimated overall 5-year survival for all patients was 89%. Local and regional tumor control as
well as survival rate were comparable with the results of other therapeutic options, i.e. radiotherapy or open supraglottic
laryngectomy. Functional results outline the advantages of endoscopic laser surgery for laryngeal carcinoma. Transoral
endoscopic CO2 laser surgery is efficacious treatment for T1 and T2 supraglottic carcinoma, and can be combined with
neck dissection and postoperative irradiation.
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Introduction
Supraglottic laryngectomy is surgical therapy with
the objectives of complete removal of a tumor arising on
the epiglottis, aryepiglottic folds or ventricular folds, and
preservation of the three main laryngeal functions: res-
piration, respiratory tract protection, and phonation. To-
day, two main surgical approaches are widely used: open
and endoscopic supraglottic laryngectomy. Open laryn-
gectomy was introduced by Alonso, who initially per-
formed the procedure in two steps. Later it was modified
by Ogura, who introduced one-step supraglottic laryn-
gectomy1,2. The endoscopic treatment of supraglottic car-
cinoma emerged in the late 1930s, with Jackson’s de-
scription of laryngoscope and punch biopsy forceps for
excision of suprahyoid epiglottic carcinoma. Technologic
developments such as the introduction of surgical micro-
scope in the 1950s, the introduction of suspensive micro-
laryngoscopy in the 1960s, and the use of carbon dioxide
laser for endolaryngeal surgery in the 1970s, have al-
lowed for expansion of the endoscopic technique for the
treatment of supraglottic cancer3,4.
The aim of this report is to present our ten-year expe-
rience with CO2 laser microsurgery in the management
of supraglottic cancer.
Materials and Methods
During a 10-year period (from January 1, 1993 till De-
cember 31, 2002), 64 previously untreated patients with
histologically verified squamous cell carcinoma of the
supraglottis were endoscopically treated at the Univer-
sity Department of ENT, Head and Neck Surgery, Zagreb
University Hospital Center, Zagreb. There were 59 men
and five women, mean age 58 years (range 42 to 79
years). We considered patients with T1 and T2 lesions as
candidates for endoscopic resection. Twenty-nine pa-
tients had T1 and 35 patients T2 lesions (UICC-AJCC
staging, sixth edition). There were 46 (72%) patients
without regional and/or distant metastases (N0 neck),
and 18 (28%) patients with clinically positive neck lym-
phatics (N+ neck). Tumor stage distribution is pre-
sented in Table 1.
The routine preoperative examination included mag-
nifying laryngoscopy, palpation, ultrasonography, and
fine-needle aspiration of neck nodes. Computed tomogra-
phy (CT) was not routinely employed.
One of the necessities for endosopic resection is com-
plete tumor visualization. Optimal exposure and visual-
ization of supraglottic region were obtained by use of di-
rect laryngoscope and chest holder. The operations were
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carried out with a CO2 laser coupled to the operating mi-
croscope. The focus diameter of the micromanipulator
was 0.3 mm and the delivered laser energy was 12 to 20
watts in continuous mode. Bleeding from large vessels
was controlled by electrocautery. Allmost all supraglottic
tumors were treated by en bloc removal.
Epiglottic T1 tumors of suprahyoid localization with
N0 neck were not an indication for elective neck treat-
ment. There were 14 such cases. Five patients with
midline T2 tumors and N0 neck received elective radio-
therapy instead of neck dissection. Neck dissection was
performed in 45 (70%) patients: selective in 27 (42%) and
curative in 18 (28%) patients. Selective dissection in-
cluded nodal levels II–IV, whereas curative dissection
was either radical or modified radical dissection. Unilat-
eral neck dissection was performed in 19 patients with
lateral tumor localization. In 26 patients with midline tu-
mors, neck dissection was performed bilaterally. Bilat-
eral dissections were performed in two acts: the first dis-
section was done simultaneously with primary treat-
ment, and the second one was delayed by 7 to 10 days.
Thirty-three (52%) patients underwent surgical ther-
apy alone, whereas 31 (48%) patients received postopera-
tive radiotherapy. Besides the above mentioned five pa-
tients with midline T2 tumors and N0 neck who recieved
elective neck irradation, indications for radiotherapy
were positive or close resection margin of a primary tu-
mor, multiple lymph node metastases, and lymph node
metastases with extracapsular spread. Four patients had
both positive/close resection margin and N+ neck.
Survival calculations were done by the Kaplan-Meier
method using XLSTAT software for Microsoft Excel 2004
Pro (Addinsoft, NY, USA).
Results
Postoperative nasogastric intubation was often avoi-
ded in T1 cases. In others, the mean duration of naso-
gastric alimentation was 7 days (range 3 to 15 days).
Nine (14%) patients were tracheotomized, one of them
one month postoperatively because of a heavy laryngeal
edema.
The mean follow up was 46 months (range 6–88
months). Survival calculations were done by the Kaplan-
-Meier method (Table 2). Estimated overall 5-year sur-
vival for all patients was 89%. On determination of over-
all survival we considered all deaths, including those
caused by intercurrent deaths and second primary tu-
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TABLE 1
TUMOR STAGE DISTRIBUTION (UICC-AJCC STAGING,
SIXTH EDITION)
Stage No. of Patients %
I 22 34
II 24 38
III 11 17
IV 7 11
Total 64 100
There were 46 patients without regional and/or distant meta-
stases (N0 neck), and 18 patients with clinically positive neck
lymphatics (N+ neck).
TABLE 2
KAPLAN-MEIER TABLE FOR THE FIRST 4 YEARS OF
FOLLOW-UP – SURVIVAL CALCULATIONS WERE DONE BY
THE KAPLAN-MEIER METHOD
Year At risk Failed Censored
1 64 0 6
2 58 2 11
3 45 1 5
4 39 1 13
Estimated overall 5-year survival for all patients was 89%, while
estimated 5-year recurrence-free survival for all patients was 93%.
Year – year of follow up, At risk – number of followed up patients
in particular year, Failed – fatal outcome, Censored – patients
who did not complain to follow up by the end of particular year
TABLE 3
FAILURE AFTER SUPRAGLOTTIC LASER LARYNGECTOMY
Sex/Age
(yrs)
TNM Therapy Complication
Therapy for
Complications
Outcome
M/59 T2N2aM0 SGL+RND+RT Neck recurrence / Death, 31 mo
M/64 T2N1M SGL+RND+RT Bronchial cancer CT Death, 18 mo
M/57 T2N0M0 SGL+RT Local recurrence TL Alive
M/49 T2N1M0 SGL+RND+RT
Aspiration
Meta pulmo
TL
CT
Death, 23 mo
M/62 T1N1M0 SGL+RND Myocardial infarction / Death, 43 mo
M/51 T1N1M0 SGL+RND Local recurrence SGL, RT Alive
M/64 T1N0M0 SGL Lingual cancer op, RT Alive
Two patients died from tumor complications. Two patients suffered local recurrence, however, after secondary therapeutic regimen
they are still alive. Two patients developed second primary cancer (bronchial cancer and lingual cancer).
SGL – supraglottic laryngectomy, RND – radical neck dissection, RT – radiotherapy, CT – chemotherapy, TL – total laryngectomy,
op – operation
mors. The estimated 5-year recurrence-free survival for
all patients was 93%. For the determination of recur-
rence-free survival uncensored observations included lo-
cal and neck recurrences (including those successfully
managed), distant metastasis and TNM-related deaths.
We did not include patients who died due to second pri-
mary tumor and intercurrent deaths.
The causes of failure after supraglottic CO2 laser
laryngectomy are presented in Table 3. Two patients
died from tumor complications (neck recurrence, pulmo-
nary metastasis). Two patients suffered local recurrence,
however, after secondary therapeutic regimen they are
still alive. In one of these patients salvage total laryn-
gectomy was performed. Two patients developed second
primary cancer (bronchial cancer and lingual cancer).
Temporary aspiration occurred in 17 (26%) patients. One
patient suffered heavy aspiration and recurrent aspira-
tion pneumonia, thus total laryngectomy was performed
nine months after the laser procedure. Subsequently,
this patient developed pulmonary metastasis and died.
Major hemorrhage requiring surgical revision occurred
postoperatively in two patients, and was managed suc-
cesfully in both cases. Three patients developed minor la-
ryngeal stenosis as the result of laryngeal chondritis,
however, requiring no additional surgical treatment. In
all patients, the speech function was satisfactory. All
tracheotomized patients were eventually decannulated.
Discussion
Supraglottic carcinoma can be managed with surgery,
radiotherapy, and a combination of these two modalities.
The best treatment approach is still controversial. Ses-
sions et al. have recently published retrospective study in
653 patients with supraglottic laryngeal cancer, where
none of the nine treatment modalities produced a sur-
vival advantage, either overall or within stages5. The de-
cision on the treatment of supraglottic carcinoma depends
on careful patient selection and surgeon’s experience,
and is highly individual. Also, early supraglottic lesions
can be treated with either surgery or radiotherapy. The
advantages of surgery as compared with radiotherapy
are less tissue destruction, precise tumor resection, eas-
ier follow up examination, and reservation of radiother-
apy for possible tumor recurrence. The advantages of ra-
diotherapy are avoidance of postoperative morbidity and
mortality, better preservation of speech and swallowing,
and reservation of surgery for the possibly needed sal-
vage laryngectomy2. The results recorded in the manage-
ment of early stage carcinoma are similar for these two
treatment modalities. Mendenhall et al. reported on a
100% 5-year survival rate for T1 tumors and 83% for T2
tumors in patients treated with radiotherapy alone6. The
reported rates of 5-year survival rate for open horizontal
supraglottic laryngectomy range from 90% to 100% for
T1, and from 80% to 97% for T27–9.
In recent years, promising results of endoscopic CO2
laser management of supraglottic cancer have been pu-
blished3,10–14. Still, the reported series on supraglottic
cancer reveal considerable variability in therapeutic ap-
proach: the indications for laser procedure, neck
management, and postoperative irradiation are very in-
consistent. The advantages of endoscopic laser surgery
are avoidance of tracheotomy, shorter time of operative
procedure, less postoperative complications, faster swal-
lowing restitution, and lower cost of rehabilitation. In
this article we reviewed our experience in 64 patients
with supraglottic carcinoma.
In our study, we only operated patients with T1 and
T2 lesions, with or without neck metastases. None of the
patients inculded in this study had T3 tumor. Iro et al.
emphasize that the indication for transoral surgery of T3
lesions should be considered with restraint11. Some au-
thors described their experience with laser resection of
T3 lesions. Motta et al. have recently published their ex-
perience on 116 supraglottic tumors, where they had 18
patients with T3 lesions (T3N0M0)12. They have re-
ported actuarial 5-year local control in these patients to
be 77%, and emphasized that in T3 lesions CO2 laser
should be implemented in those cases in which radical
excision by endoscopic route is feasible. In the last years
we also performed several endoscopic procedures on pa-
tients with T3 lesions (data were not included in this
study), but solely for the lesions that were completely vi-
sualized through endoscope, and without neck disease.
Short-term results seems to promising, but we need lon-
ger follow-up to draw the conclusions. Adequate expo-
sure and visualization of the tumor is crucial for safe re-
section. If adequate resection margins are obtained,
oncologic results of transoral laser surgery should be
comparable to those of classic transcervical resection.
Eighteen of our patients had clinically positive neck
lymph nodes. Most of the series on transoral laser micro-
surgery included patients with positive nodal disease,
some of them with a significant ratio of stage III and IV
patients15. It is well known that the presence of regional
metastases results in cure rates that are approximately
half those obtainable if metastasis to regional lymphatics
is not present. Of 12 followed-up patients with stage III
and IV cancer we had five (42%) patients with treatment
failure/complication, compared with only 2 (6%) failures
in 35 patients with early-stage carcinoma.
Nowadays, the management of clinically N+ neck is
generally unique; however, the appropriate treatment of
the clinically N0 neck is still a controversial issue2,16.
Neck relapse remains a significant cause of failure in pa-
tients with supraglottic cancer. Levendag and colleagues
found a 35 percent rate of nodal disease either upon elec-
tive dissection or subsequent relapse in a series of stage I
and II supraglottic cancers9. Given the risk of disease and
its morbidity, elective neck dissection is warranted in
most cases of supraglottic cancer.
In our study, we have applied the following algorhytm
for neck management: in patients with N+ neck, either
radical or modified radical dissection was performed; in
patients with N0 neck, only epiglottic T1 tumors of
suprahyoid localization were not an indication for elec-
tive treatment; most of the other patients were treated
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with neck dissection, and five patients with midline T2
tumors received radiotherapy instead of neck dissection.
Lateral tumor localization was an indication for unilat-
eral neck dissection, whereas in midline cases bilateral
neck dissection was performed.
The supraglottic area is richly supplied with lym-
phatics and the incidence of occult metastases is around
30%17. The repetitive pattern of metastasizing (mostly
affecting levels II, III and IV) has introduced lateral neck
dissection as the treatment of choice. Elective lateral
neck dissection of levels II–IV is recommended in T2–T4
N0 supraglottic cancers18; and according to Iro even in
stage I disease11. Myers and Alvi conclude that patients
with bilateral neck operation have a lower incidence of
postoperative recurrences and even suggest bilateral
neck dissection in all patients with supraglottic cancer2.
In midline cases, bilateral neck dissection is mandatory.
In pN+ cases as well as in those where the primary tu-
mor specimen shows positive margins postoperative ra-
diotherapy should also be used13.
The reported incidence of adjuvant radiotherapy dif-
fers among authors and ranges from 2% to 45.4%10,11. We
considered adjuvant radiotherapy for patients with
lymph node metastases with extracapsular spread, and
positive or close resection margins. On deciding on post-
operative radiotherapy Rudert also considers the size of
primary tumor13. In case of positive margins, Ambrosch
recommends repeated resections10.
Functional results recorded in our study significantly
outline those after open supraglottic laryngectomies and
have been reported previously. Besides general avoidance
of tracheotomy, less postoperative complications, faster
swallowing restitution, and overall therapy and rehabi-
litalion cost benefits, we recorded a significantly lower
rate of aspiration. Aspiration was recorded on videoflou-
roscopy in 30% of our patients, compared to almost 90%
of patients who underwent classic supraglottic laryn-
gectomy19. The lower rate of aspiration and the absence
of some other complications after endoscopic supraglot-
tic laryngectomy by CO2 laser have been ascribed to the
preservation of vital structures that have important ro-
les in the act of swallowing, such as the base of the
tongue, prelaryngeal muscles, hyoid bone, arytenoid car-
tilage and extralaryngeal part of both superior laryngeal
nerves, enabling restitution of the sensory function of
the larynx and its normal mobility.
None of our patients had any clinical symptoms of
dysphagia. Also, in many of our patients we avoided post-
operative nasogastric intubation. Nowadays, our prefer-
ence is general avoidance of nasogastric intubation, un-
less the signs of aspiration are present.
Conclusion
The use of endoscopic laser surgery for supraglottic
tumor depends on the tumor localization and expansion,
patient’s general condition, surgeon’s experience, and
devices available. T1 and T2 supraglottic lesions could be
successfully managed endoscopically, either by sole surgi-
cal therapy of primary tumor or by its combination with
adjuvant radiotherapy or neck dissection. The presence
of regional metastases results in much lower cure rates.
Our results prove the validity of supraglottic laryngecto-
my by CO2 laser as a method of treatment for carcinoma
of the larynx.
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NA[E 10-GODI[NJE ISKUSTVO U ENDOSKOPSKOM KIRUR[KOM LIJE^ENJU
SUPRAGLOTI^KIH KARCINOMA POMO]U CO2 LASERA
S A @ E T A K
U radu smo opisali na{e iskustvo u kirur{kom lije~enju primarnih supragloti~kih karcinoma pomo}u CO2 lasera. U
razdoblju od 10 godina u 64 bolesnika je ura|ena kurativna endoskopska supragloti~ka laringektomija. 29 bolesnika
imalo je T1, a 35 bolesnika T2 lezije grkljana. 46 bolesnika nije imalo regionalne niti udaljene metastaze (N0 vrat), dok
je 18 bolesnika imalo metastatske promjene u vratu (N+ vrat). 33 (52%) bolesnika lije~ena su samo kirur{ki, dok je kod
31 (48%) bolesnika kirur{ko lije~enje nadopunjeno radioterapijom. O~ekivano 5-godi{nje pre`ivljenje za sve bolesnike
iznosilo je 89%. Lokalna i regionalna kontrola tumora, kao i stopa pre`ivljenja u na{ih bolesnika mo`e se usporediti s
ishodima drugih vrsta terapije ove bolesti, poput primarne iradijacije ili otvorene supragloti~ke laringektomije. Pred-
nost endoskopske laserske kirurgije grkljana nad ostalim metodama je u dobrim funkcijskim rezultatima. Transoralna
endoskopska kirurgija CO2 laserom je u~inkovita u lije~enju T1 i T2 supragloti~nih tumora grkljana i mo`e se kom-
binirati s disekcijom vrata i postoperativnim zra~enjem.
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